The Clinical Efficacy And Prognostic Analysis Of Imatinib In Treatment Of Advanced Gastrointestinal Stromal Tumors

Objective:To study the efficacy and prognostic analysis of imatinib in the treatment of patients with advanced GIST.Methods :44 advanced GIST patients between January 2010 and June 2014 were analyzed retrospectively,and prognostic fators were evaluated by RECIST 1.1.All patients were given imatinib mesylate orally with initial dose of 400 mg per day.Kaplan-Meier method was used for survival statistics and Cox proportional hazard model for multivariable independent risk factors analyses.Result:44 were evaluable for the response.Of these 44 patients,4 of them(9.1%)achieved complete response(CR),27(61.4%)achieved partial response(PR),10(20.2%)had stable disease(SD)and 3(6.8%)had progression disease(PD).The objective response rate was70.5%.The median progression-free survival was 35.0 months(95%CI: 23.8~46.2);the 1-,2-,3-,5-year survival rates were 95.5%,93.1%,88.0%and 73.3%,respectively.According to the Cox proportional hazards regression model analysis,GIST originated from primary location,tumor diameter,mitotic rate were the independent factors affecting the PFS.The primary location,tumor diameter were the independent factors affecting the OS.Conclusion:Advanced GIST patients benefit from imatinib therapy.Primary location,tumor diameter,mitotic rate were the main influencing factors for advanced GIST.